Different DOACs Control Inflammation in Cardiac Ischemia-Reperfusion Differently

Response by Petzold et al to Letter Regarding Article, "Rivaroxaban Reduces Arterial Thrombosis by Inhibition of Fxa-Driven Platelet Activation via Protease Activated Receptor-1"

(2020) Tobias Petzold et al.   CIRCULATION RESEARCH

Thromboinflammation: Challenges of Therapeutically Targeting Coagulation and other Host Defence Mechanisms

(2019) Shaun P. Jackson et al.   BLOOD

Cell-Type-Specific Gene Expression Profiling in Adult Mouse Brain Reveals Normal and Disease-State Signatures

(2019) Nicolas Merienne et al.   Cell Reports

Platelet Extracellular Vesicles Drive Inflammasome-IL1β-dependent Lung Injury in Sickle Cell Disease

(2019) Ravi Vats et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Exploring traditional and nontraditional roles for thrombomodulin

(2018) Houra Loghmani et al.   BLOOD

Activated protein C, protease activated receptor 1, and neuroprotection

(2018) John H. Griffin et al.   BLOOD

Risk of Myocardial Infarction in Anticoagulated Patients With Atrial Fibrillation

(2018) Christina Ji-Young Lee et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Tissue Factor at the crossroad of coagulation and cell signaling

(2018) Hortensia Zelaya et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation

(2018) Juraj Sokol et al.   JOURNAL OF THROMBOSIS AND THROMBOLYSIS

Cell biology of activated protein C

(2018) Khurrum Shahzad et al.   CURRENT OPINION IN HEMATOLOGY

Non-vitamin K oral anticoagulants (NOAC) and the risk of myocardial infarction: Differences between factor IIa and factor Xa inhibition?

(2018) Amin Polzin et al.   PHARMACOLOGY & THERAPEUTICS

Homeostatic effects of coagulation protease-dependent signaling and protease activated receptors

(2017) B. Isermann   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The Long Noncoding RNA Landscape of the Ischemic Human Left VentricleCLINICAL PERSPECTIVE

(2017) Louis A. Saddic et al.   Circulation-Cardiovascular Genetics

Maternal extracellular vesicles and platelets promote preeclampsia via inflammasome activation in trophoblasts

(2016) S. Kohli et al.   BLOOD

Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation

(2016) Francisco Marín et al.   EXPERT OPINION ON PHARMACOTHERAPY

Protease-activated receptor 4 deficiency offers cardioprotection after acute ischemia reperfusion injury

(2016) Mikhail A. Kolpakov et al.   JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY

Heatmapper: web-enabled heat mapping for all

(2016) Sasha Babicki et al.   NUCLEIC ACIDS RESEARCH

Anti Xa oral anticoagulants inhibit in vivo platelet activation by modulating glycoprotein VI shedding

(2016) Pasquale Pignatelli et al.   PHARMACOLOGICAL RESEARCH

Risk of Myocardial Infarction in Patients with Long-Term Non-Vitamin K Antagonist Oral Anticoagulant Treatment

(2016) Adrienn Tornyos et al.   PROGRESS IN CARDIOVASCULAR DISEASES

Oral thrombin inhibitor aggravates platelet adhesion and aggregation during arterial thrombosis

(2016) T. Petzold et al.   Science Translational Medicine

Pretreatment with rivaroxaban attenuates stroke severity in rats by a dual antithrombotic and anti-inflammatory mechanism

(2016) Peter Kraft et al.   THROMBOSIS AND HAEMOSTASIS

A direct thrombin inhibitor suppresses protein C activation and factor Va degradation in human plasma: Possible mechanisms of paradoxical enhancement of thrombin generation

(2016) Chikako Kamisato et al.   THROMBOSIS RESEARCH

Expression of pro-inflammatory genes in human endothelial cells: Comparison of rivaroxaban and dabigatran

(2016) Peter Ellinghaus et al.   THROMBOSIS RESEARCH

Dabigatran and Argatroban Diametrically Modulate Thrombin Exosite Function

(2016) Calvin H. Yeh et al.   PLoS One

Molecular mechanisms regulating NLRP3 inflammasome activation

(2015) Eun-Kyeong Jo et al.   Cellular & Molecular Immunology

Effects of Rivaroxaban on Platelet Activation and Platelet–Coagulation Pathway Interaction

(2015) Elisabeth Perzborn et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Paradoxical enhancement of the intrinsic pathway-induced thrombin generation in human plasma by melagatran, a direct thrombin inhibitor, but not edoxaban, a direct factor Xa inhibitor, or heparin

(2015) Taketoshi Furugohri et al.   THROMBOSIS RESEARCH

Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials

(2014) N. van Es et al.   BLOOD

NLRP3 Inflammasome as a Novel Player in Myocardial Infarction

(2014) Masafumi Takahashi   International Heart Journal

Direct thrombin inhibitors, but not the direct factor Xa inhibitor rivaroxaban, increase tissue factor-induced hypercoagulabilityin vitroandin vivo

(2014) E. Perzborn et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance

(2014) Charles Wang et al.   NATURE BIOTECHNOLOGY

The complete N-terminal extension of heparin cofactor II is required for maximal effectiveness as a thrombin exosite 1 ligand

(2013) Amanda J Boyle et al.   BMC BIOCHEMISTRY

Biased signalling and proteinase-activated receptors (PARs): targeting inflammatory disease

(2013) M D Hollenberg et al.   BRITISH JOURNAL OF PHARMACOLOGY

Proteinase-activated receptors (PARs) – focus on receptor-receptor-interactions and their physiological and pathophysiological impact

(2013) Frank Gieseler et al.   Cell Communication and Signaling

The pathogenesis of cardiac fibrosis

(2013) Ping Kong et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Protease-Activated Receptor 1 Inhibition by SCH79797 Attenuates Left Ventricular Remodeling and Profibrotic Activities of Cardiac Fibroblasts

(2013) Dmitry L. Sonin et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials

(2013) Christian T Ruff et al.   LANCET

Dabigatran Association With Higher Risk of Acute Coronary Events

(2012) Ken Uchino   ARCHIVES OF INTERNAL MEDICINE

Dabigatran and risk of myocardial infarction

(2012) John W. Eikelboom et al.   Nature Reviews Cardiology

Activated protein C ameliorates diabetic nephropathy by epigenetically inhibiting the redox enzyme p66Shc

(2012) F. Bock et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Plasma proteomics of patients with non-valvular atrial fibrillation on chronic anti-coagulation with warfarin or a direct factor Xa inhibitor

(2012) Mark Chan et al.   THROMBOSIS AND HAEMOSTASIS

Coronary and mortality risk of novel oral antithrombotic agents: a meta-analysis of large randomised trials

(2012) Koon-Hou Mak   BMJ Open

Thermodynamic Compensation upon Binding to Exosite 1 and the Active Site of Thrombin

(2011) Nicholas A. Treuheit et al.   BIOCHEMISTRY

Treatment with an oral direct thrombin inhibitor decreases platelet activity but increases markers of inflammation in patients with myocardial infarction

(2011) C. Christersson et al.   JOURNAL OF INTERNAL MEDICINE

Apixaban versus Warfarin in Patients with Atrial Fibrillation

(2011) Christopher B. Granger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of Thrombin Fragment (TP508) on Myocardial Ischemia Reperfusion Injury in a Model of Type 1 Diabetes Mellitus

(2010) L. M. Chu et al.   CIRCULATION

Oral Rivaroxaban for Symptomatic Venous Thromboembolism

(2010)   NEW ENGLAND JOURNAL OF MEDICINE

Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity

(2010) Joachim Stangier et al.   THROMBOSIS AND HAEMOSTASIS

Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement

(2009) G. L. Van Sluis et al.   BLOOD

Apixaban, an Oral, Direct, Selective Factor Xa Inhibitor, in Combination With Antiplatelet Therapy After Acute Coronary Syndrome

(2009)   CIRCULATION

Parstatin(1-26): The Putative Signal Peptide of Protease-Activated Receptor 1 Confers Potent Protection from Myocardial Ischemia-Reperfusion Injury

(2009) K. V. Routhu et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Endogenous activated protein C signaling is critical to protection of mice from lipopolysaccaride-induced septic shock

(2009) J. XU et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS